Publications by authors named "O Theisen"
Background: Thanks to an improved therapeutic regimen in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), 5 year-overall survival now exceeds 90%. Unfortunately, the 25% of children who relapse have an initial poor prognosis, potentially driven by pre-existing or emerging molecular anomalies. The latter are initially and essentially identified by cytogenetics.
View Article and Find Full Text PDFArticle Synopsis
- - Myelodysplastic neoplasms (MDS) are blood disorders often linked to chromosomal abnormalities, with 40-45% of cases showing these changes at diagnosis and up to 80% in post-treatment MDS.
- - Recent changes in classifications by the WHO and ICC have introduced a new entity focusing on biallelic TP53 inactivation, which necessitates detailed genetic investigations, particularly on the TP53 locus.
- - While molecular features are becoming more essential for diagnosing and prognosing MDS, traditional cytogenetics—including karyotyping—remains crucial, and new scoring systems have been developed combining genetic mutations with established cytogenetic parameters.
Myeloproliferative neoplasms, mastocytosis, myeloid/lymphoid neoplasms with hypereosinophilia and tyrosine kinase gene fusions, and myelodysplastic/myeloproliferative neoplasms are clonal hematopoietic cancers that, with the exception of certain entities, have an indolent course. In addition to their increasingly important role in the diagnosis of these entities, as shown by the recent classification of hematolymphoid tumors in the 5th edition of the World Health Organization and the International Consensus Classification of myeloid neoplasms and acute leukemias, identification of the profile of acquired genetic abnormalities is essential for adapting patient management and early detection of patients at high risk of progression. Alongside molecular abnormalities, cytogenetic abnormalities play an important role in the diagnosis, prognosis and follow-up of these diseases.
View Article and Find Full Text PDFArticle Synopsis
- In acute myeloid leukaemia (AML), interleukin-6 (IL-6) is linked to chemotherapy resistance and worse patient outcomes, prompting researchers to explore tocilizumab, an anti-IL-6 receptor monoclonal antibody, as a potential treatment in combination with standard chemotherapy.
- A phase 1 trial at Nantes University Hospital tested three escalating doses of tocilizumab in adults with newly diagnosed or relapsed AML, aiming to determine the maximum tolerated dose (MTD) while monitoring safety and treatment responses.
- Of the 12 patients treated, no significant toxicities related to tocilizumab were observed, nine out of ten evaluable patients had a positive response to the treatment, indicating
Quantifying uncertainty associated with our models is the only way we can express how much we know about any phenomenon. Incomplete consideration of model-based uncertainties can lead to overstated conclusions with real-world impacts in diverse spheres, including conservation, epidemiology, climate science, and policy. Despite these potentially damaging consequences, we still know little about how different fields quantify and report uncertainty.
View Article and Find Full Text PDF